fromNature
1 week agoFasting boosts breast cancer therapy efficacy via glucocorticoid activation - Nature
Hormone receptor-positive (HR+) breast cancer accounts for 75% of all breast cancer diagnoses, and endocrine therapies represent the mainstay of treatment for patients with HR+ breast cancer, in both adjuvant and metastatic settings1. Yet, the efficacy of standard endocrine therapies is limited by primary or acquired resistance2. Periodic fasting enhances the efficacy of endocrine therapies against HR+ breast cancer and delays acquired therapy resistance in animal models3.
Medicine